Innoviva Inc (INVA)vsRegeneron Pharmaceuticals Inc (REGN)
INVA
Innoviva Inc
$20.66
+0.19%
HEALTHCARE · Cap: $1.53B
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 3431% more annual revenue ($15.53B vs $440.00M). INVA leads profitability with a 81.2% profit margin vs 27.9%. INVA appears more attractively valued with a PEG of 0.26. INVA earns a higher WallStSmart Score of 85/100 (A-).
INVA
Exceptional Buy85
out of 100
Grade: A-
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INVA.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 38 in profit
Keeps 81 of every $100 in revenue as profit
Strong operational efficiency at 43.3%
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : INVA
The strongest argument for INVA centers on PEG Ratio, P/E Ratio, Price/Book. Profitability is solid with margins at 81.2% and operating margin at 43.3%. Revenue growth of 19.3% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : INVA
The primary concerns for INVA are Market Cap, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
INVA carries more volatility with a beta of 0.33 — expect wider price swings.
INVA is growing revenue faster at 19.3% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INVA scores higher overall (85/100 vs 66/100), backed by strong 81.2% margins and 19.3% revenue growth. REGN offers better value entry with a 44.4% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?